Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beyond Ranbaxygate: trust, mistrust and Indian generics

This article was originally published in Scrip

Executive Summary

Okay, first things first. This isn't about a patriotic defense of any defrauding company, even if it is the once iconic Ranbaxy Laboratories. This also isn't about taking anything away from the courageous whistleblower, Dinesh Thakur, a former director and global head, research information and portfolio management at the firm, who exposed the rot in the now Daiichi Sankyo-controlled company and helped the US FDA and Department of Justice unravel a complicated trail of falsified records and manufacturing practices that violated GMP norms.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC021535

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel